Johnson & Johnson/AbbVie Inc. 's Imbruvica (ibrutinib) has rapidly established itself as standard of care in relapsed/refractory chronic lymphocytic leukaemia and will increasingly move into the first-line setting following its recent approval by the FDA for that use in patients with CLL, analysts say.
That accolade was won after Imbruvica showed good efficacy in first-line CLL without the need for a chemotherapy backbone. Whether...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

